These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 33651496)
1. [Expanded Access in The Netherlands: prescribing unregistered medicine]. Polak TB; Cucchi DGJ; van Rosmalen J Ned Tijdschr Geneeskd; 2021 Feb; 165():. PubMed ID: 33651496 [TBL] [Abstract][Full Text] [Related]
2. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands. Bunnik EM; Aarts N BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313 [TBL] [Abstract][Full Text] [Related]
3. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs. Puthumana J; Miller JE; Kim J; Ross JS JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072 [TBL] [Abstract][Full Text] [Related]
4. Should patients in need be given access to experimental drugs? Caplan AL; Bateman-House A Expert Opin Pharmacother; 2015 Jun; 16(9):1275-9. PubMed ID: 26001178 [TBL] [Abstract][Full Text] [Related]
5. Expanded access to investigational drugs in psychiatry: A systematic review. Vermeulen SF; Polak TB; Bunnik EM Psychiatry Res; 2023 Nov; 329():115554. PubMed ID: 37890403 [TBL] [Abstract][Full Text] [Related]
6. Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs. Bunnik EM; Aarts N; van de Vathorst S Health Policy; 2018 Sep; 122(9):977-983. PubMed ID: 29935731 [TBL] [Abstract][Full Text] [Related]
7. Dilemmas in the compassionate supply of investigational cancer drugs. Lewis JR; Lipworth W; Kerridge I; Doran E Intern Med J; 2014 Sep; 44(9):841-5. PubMed ID: 25201421 [TBL] [Abstract][Full Text] [Related]
8. Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication. Hoerger M Death Stud; 2016; 40(2):113-20. PubMed ID: 26313583 [TBL] [Abstract][Full Text] [Related]
9. Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients. Jerome RN; Edwards TL; Boswell HC; Bernard GR; Harris PA; Pulley JM Acad Med; 2016 Mar; 91(3):305-9. PubMed ID: 26445080 [TBL] [Abstract][Full Text] [Related]
10. Before It's Too Late: Multistakeholder Perspectives on Compassionate Access to Investigational Drugs for Pediatric Patients With Cancer. Gerasimov E; Donoghue M; Bilenker J; Watt T; Goodman N; Laetsch TW Am Soc Clin Oncol Educ Book; 2020 May; 40():1-10. PubMed ID: 32412804 [TBL] [Abstract][Full Text] [Related]
11. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes. Finkelstein PE AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587 [No Abstract] [Full Text] [Related]
12. Single-patient expanded access: A primer for pharmacists. Smith AJF; Redic KA Am J Health Syst Pharm; 2022 Nov; 79(23):2118-2127. PubMed ID: 36056791 [TBL] [Abstract][Full Text] [Related]
13. Oversight of Right-to-Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs. Chapman CR; Eckman J; Bateman-House AS Ethics Hum Res; 2020 Jan; 42(1):2-13. PubMed ID: 31967412 [TBL] [Abstract][Full Text] [Related]
14. Oncology Expanded Access and FDA's Project Facilitate. Scepura B; Chan M; Kim T; Boehmer J; Goldberg KB; Pazdur R Oncologist; 2021 Oct; 26(10):e1880-e1882. PubMed ID: 34288259 [TBL] [Abstract][Full Text] [Related]
15. Increasing Use of Compassionate Use/Managed Access Channels to Obtain Medicines for Use in COVID-19. Aliu P; Sarp S; Fitzsimmons P Clin Pharmacol Ther; 2021 Jul; 110(1):26-28. PubMed ID: 33326600 [No Abstract] [Full Text] [Related]
16. Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center. Stout J; Smith C; Buckner J; Adjei AA; Wentworth M; Tilburt JC; Master Z PLoS One; 2021; 16(12):e0261478. PubMed ID: 34919568 [TBL] [Abstract][Full Text] [Related]
17. Characterizing expanded access and compassionate use programs for experimental drugs. Miller JE; Ross JS; Moch KI; Caplan AL BMC Res Notes; 2017 Jul; 10(1):350. PubMed ID: 28754150 [TBL] [Abstract][Full Text] [Related]
18. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved? McKee AE; Markon AO; Chan-Tack KM; Lurie P J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646 [TBL] [Abstract][Full Text] [Related]
19. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform. Rossen BR Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746 [TBL] [Abstract][Full Text] [Related]
20. Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs. Rozenberg O; Greenbaum D Am J Bioeth; 2020 Jul; 20(7):89-92. PubMed ID: 32716805 [No Abstract] [Full Text] [Related] [Next] [New Search]